Daewoong Pharmaceutical acquires sale right and license of Sandoz’s osteoporosis treatment

Published: 2017-10-13 15:39:33

Updated: 2017-10-13 15:39:33

Daewoong Pharmaceutical(CEO Jong-Wook Lee) announce the company acquired a Korean sale right and license of ‘Zoledronic Acid Inj 5mg/100ml,’ a osteoporosis treatment, from Novartis and Sandoz Korea.

Under the distribution/promotion agreement with Sandoz Korea, Daewoong Pharmaceutical has exclusively sold ‘Sandoz Zoledron Inj 5mg/100ml’ in Korea since 2014.

‘Sandoz Zoledron Inj,’ the most well...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.